Search Results - "Ubaldi, Martina"

Circulating hsa-miR-323b-3p in Huntington's Disease: A Pilot Study by Ferraldeschi, Michela, Romano, Silvia, Giglio, Simona, Romano, Carmela, Morena, Emanuele, Mechelli, Rosella, Annibali, Viviana, Ubaldi, Martina, Buscarinu, Maria Chiara, Umeton, Renato, Sani, Gabriele, Vecchione, Andrea, Salvetti, Marco, Ristori, Giovanni

“…The momentum of gene therapy in Huntington's disease (HD) deserves biomarkers from easily accessible fluid. We planned a study to verify whether plasma miRNome…”
Get full text

Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study by Bai, Xue, Shaheen, Ahmed, Grieco, Charlotte, d’Arienzo, Paolo D., Mina, Florentia, Czapla, Juliane A., Lawless, Aleigha R., Bongiovanni, Eleonora, Santaniello, Umberto, Zappi, Helena, Dulak, Dominika, Williamson, Andrew, Lee, Rebecca, Gupta, Avinash, Li, Caili, Si, Lu, Ubaldi, Martina, Yamazaki, Naoya, Ogata, Dai, Johnson, Rebecca, Park, Benjamin C., Jung, Seungyeon, Madonna, Gabriele, Hochherz, Juliane, Umeda, Yoshiyasu, Nakamura, Yasuhiro, Gebhardt, Christoffer, Festino, Lucia, Capone, Mariaelena, Ascierto, Paolo Antonio, Johnson, Douglas B., Lo, Serigne N., Long, Georgina V., Menzies, Alexander M., Namikawa, Kenjiro, Mandala, Mario, Guo, Jun, Lorigan, Paul, Najjar, Yana G., Haydon, Andrew, Quaglino, Pietro, Boland, Genevieve M., Sullivan, Ryan J., Furness, Andrew J.S., Plummer, Ruth, Flaherty, Keith T.

Get full text

Delayed cold-type autoimmune hemolytic anemia responding to Rituximab in a melanoma patient treated with Ipilimumab and Nivolumab by Ubaldi, Martina, Sergi, Maria Chiara, Falcinelli, Flavio, Mandalà, Mario

Get full text

Tracking and tackling the tumor dynamics clonal evolution: osimertinib rechallenge after interval therapy might be an effective treatment approach in epidermal growth factor receptor ( EGFR )-mutant non-small cell lung cancer (NSCLC) by Metro, Giulio, Bonaiti, Angelo, Birocchi, Ilaria, Marasciulo, Francesca, Ubaldi, Martina, Metelli, Niccolò, Minotti, Vincenzo, Addeo, Alfredo

Get full text

Efficacy of anti PD-1 therapy in children and adolescent melanoma patients (MELCAYA study) by Mandalà, Mario, Ferrari, Andrea, Brecht, Ines B., Suijkerbuijk, Karijn PM, Maschke, Linda, Giannarelli, Diana, Indini, Alice, Ubaldi, Martina, Pecci, Giulia, Atkinson, Victoria, Helgadottir, Hildur, Chiaravalli, Stefano, Benannoune, Naima, Robert, Caroline, Teterycz, Pawel, Rutkowski, Piotr, Puig, Susana, Madonna, Gabriele, Kebudi, Rejin, Grynberg, Shirly, Arantes, Lidia MRB, Bien, Ewa, Krawczyk, Malgorzata, Pasquale, Maria Debora De, Dierselhuis, Miranda P., Massi, Daniela, Long, Georgina V., Ascierto, Paolo Antonio, Eggermont, Alexander M.M.

“…Data on the efficacy and safety of anti PD-1 antibodies in children and adolescents (CA) with melanoma are lacking. The aim of this study was to determine…”
Get full text

Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study by Bai, Xue, Shaheen, Ahmed, Grieco, Charlotte, d’Arienzo, Paolo D., Mina, Florentia, Czapla, Juliane A., Lawless, Aleigha R., Bongiovanni, Eleonora, Santaniello, Umberto, Zappi, Helena, Dulak, Dominika, Williamson, Andrew, Lee, Rebecca, Gupta, Avinash, Li, Caili, Si, Lu, Ubaldi, Martina, Yamazaki, Naoya, Ogata, Dai, Johnson, Rebecca, Park, Benjamin C., Jung, Seungyeon, Madonna, Gabriele, Hochherz, Juliane, Umeda, Yoshiyasu, Nakamura, Yasuhiro, Gebhardt, Christoffer, Festino, Lucia, Capone, Mariaelena, Ascierto, Paolo Antonio, Johnson, Douglas B., Lo, Serigne N., Long, Georgina V., Menzies, Alexander M., Namikawa, Kenjiro, Mandala, Mario, Guo, Jun, Lorigan, Paul, Najjar, Yana G., Haydon, Andrew, Quaglino, Pietro, Boland, Genevieve M., Sullivan, Ryan J., Furness, Andrew J.S., Plummer, Ruth, Flaherty, Keith T.

“…Both dabrafenib/trametinib (D/T) and anti-PD-1 monotherapy (PD-1) are approved adjuvant therapies for patients with stage III BRAF V600-mutant melanoma…”
Get full text

Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort studyResearch in context by Xue Bai, Ahmed Shaheen, Charlotte Grieco, Paolo D. d’Arienzo, Florentia Mina, Juliane A. Czapla, Aleigha R. Lawless, Eleonora Bongiovanni, Umberto Santaniello, Helena Zappi, Dominika Dulak, Andrew Williamson, Rebecca Lee, Avinash Gupta, Caili Li, Lu Si, Martina Ubaldi, Naoya Yamazaki, Dai Ogata, Rebecca Johnson, Benjamin C. Park, Seungyeon Jung, Gabriele Madonna, Juliane Hochherz, Yoshiyasu Umeda, Yasuhiro Nakamura, Christoffer Gebhardt, Lucia Festino, Mariaelena Capone, Paolo Antonio Ascierto, Douglas B. Johnson, Serigne N. Lo, Georgina V. Long, Alexander M. Menzies, Kenjiro Namikawa, Mario Mandala, Jun Guo, Paul Lorigan, Yana G. Najjar, Andrew Haydon, Pietro Quaglino, Genevieve M. Boland, Ryan J. Sullivan, Andrew J.S. Furness, Ruth Plummer, Keith T. Flaherty

“…Background: Both dabrafenib/trametinib (D/T) and anti-PD-1 monotherapy (PD-1) are approved adjuvant therapies for patients with stage III BRAF V600-mutant…”
Get full text